Gene Variant Test Distinguishes Individuals with Ankylosing Spondylitis
By LabMedica International staff writers Posted on 22 Dec 2014 |
Image: X-ray showing bamboo spine in a patient with ankylosing spondylitis (Photo courtesy of Steven Fruitsmaak).
Natural variations in an immune system enzyme that can leave individuals susceptible to the inflammatory rheumatic disease ankylosing spondylitis have been discovered.
Better understanding of these variations could lead to a genetic test that helps people become aware of the risk of ankylosing spondylitis earlier and improve disease prognosis. Ankylosing spondylitis (AS) is a chronic inflammatory disease that mainly affects joints in the spine and in severe cases it can lead to complete fusion and rigidity of the spine, a condition that is sometimes called "bamboo spine."
Scientists at the University of Southampton (UK) characterized the full-length coding sequence of individual endoplasmic reticulum aminopeptidase 1(ERAP1) allotypes from a cohort of AS cases and non-AS controls, revealing 13 different allotypes, and propose a standardized nomenclature reflecting the highly polymorphic nature of ERAP1. These ERAP1 allotypes revealed a level of disease distinction with the frequency of those identified in non-AS controls, significantly different from those observed in AS cases. The characterization of allotype pairs revealed stratification of AS cases and control groups because no combination was shared between groups.
The investigators isolated ERAP1 from complementary DNA (cDNA) and polymerase chain reaction (PCR) amplicons were cloned into vectors and sequenced to identify individual allotypes. ERAP1 allotype sequences were aligned and phylogenetic analysis was performed. The team also employed cell lines, T-cell activation, and major histocompatibility complex (MHC I) recovery assays to analyze the specimens. Cells were analyzed by flow cytometry with a BD FACS Canto II (BD Bioscience; Oxford, UK). Expression of ERAP1 was determined by immunoblots.
The authors concluded that their study provides a framework for understanding how ERAP1 function could impact on disease pathogenesis and how the distinct allotype combinations in AS cases may serve as biomarkers for disease stratification and a target for treatment. Tim Elliott, PhD, co-leader of the study and professor of Experimental Medicine at Southampton, said, “These natural variations in ERAP1, which are normally involved in T-cell immunity, predispose individuals to ankylosing spondylitis. We have also discovered how variations in ERAP1 change its enzyme function and this means that it might actually be a target for developing new drugs to treat ankylosing spondylitis.” The study was published on December 9, 2014, in the journal Proceedings of the National Academy of Sciences of the United States of America (PNAS).
Related Links:
University of Southampton
BD Bioscience
Better understanding of these variations could lead to a genetic test that helps people become aware of the risk of ankylosing spondylitis earlier and improve disease prognosis. Ankylosing spondylitis (AS) is a chronic inflammatory disease that mainly affects joints in the spine and in severe cases it can lead to complete fusion and rigidity of the spine, a condition that is sometimes called "bamboo spine."
Scientists at the University of Southampton (UK) characterized the full-length coding sequence of individual endoplasmic reticulum aminopeptidase 1(ERAP1) allotypes from a cohort of AS cases and non-AS controls, revealing 13 different allotypes, and propose a standardized nomenclature reflecting the highly polymorphic nature of ERAP1. These ERAP1 allotypes revealed a level of disease distinction with the frequency of those identified in non-AS controls, significantly different from those observed in AS cases. The characterization of allotype pairs revealed stratification of AS cases and control groups because no combination was shared between groups.
The investigators isolated ERAP1 from complementary DNA (cDNA) and polymerase chain reaction (PCR) amplicons were cloned into vectors and sequenced to identify individual allotypes. ERAP1 allotype sequences were aligned and phylogenetic analysis was performed. The team also employed cell lines, T-cell activation, and major histocompatibility complex (MHC I) recovery assays to analyze the specimens. Cells were analyzed by flow cytometry with a BD FACS Canto II (BD Bioscience; Oxford, UK). Expression of ERAP1 was determined by immunoblots.
The authors concluded that their study provides a framework for understanding how ERAP1 function could impact on disease pathogenesis and how the distinct allotype combinations in AS cases may serve as biomarkers for disease stratification and a target for treatment. Tim Elliott, PhD, co-leader of the study and professor of Experimental Medicine at Southampton, said, “These natural variations in ERAP1, which are normally involved in T-cell immunity, predispose individuals to ankylosing spondylitis. We have also discovered how variations in ERAP1 change its enzyme function and this means that it might actually be a target for developing new drugs to treat ankylosing spondylitis.” The study was published on December 9, 2014, in the journal Proceedings of the National Academy of Sciences of the United States of America (PNAS).
Related Links:
University of Southampton
BD Bioscience
Latest Molecular Diagnostics News
- Blood Proteins Could Warn of Cancer Seven Years before Diagnosis
- New DNA Origami Technique to Advance Disease Diagnosis
- Ultrasound-Aided Blood Testing Detects Cancer Biomarkers from Cells
- New Respiratory Syndromic Testing Panel Provides Fast and Accurate Results
- New Synthetic Biomarker Technology Differentiates Between Prior Zika and Dengue Infections
- Novel Biomarkers to Improve Diagnosis of Renal Cell Carcinoma Subtypes
- RNA-Powered Molecular Test to Help Combat Early-Age Onset Colorectal Cancer
- Advanced Blood Test to Spot Alzheimer's Before Progression to Dementia
- Multi-Omic Noninvasive Urine-Based DNA Test to Improve Bladder Cancer Detection
- First of Its Kind NGS Assay for Precise Detection of BCR::ABL1 Fusion Gene to Enable Personalized Leukemia Treatment
- Urine Test to Revolutionize Lyme Disease Testing
- Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease
- New Genetic Testing Procedure Combined With Ultrasound Detects High Cardiovascular Risk
- Blood Samples Enhance B-Cell Lymphoma Diagnostics and Prognosis
- Blood Test Predicts Knee Osteoarthritis Eight Years Before Signs Appears On X-Rays
- Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans